Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program

S. Bruno, S. Bollani, A. L. Zignego, J. M. Pascasio, C. Magni, A. Ciancio, M. Caremani, A. Mangia, S. Marenco, S. Piovesan, L. Chemello, S. Babudieri, A. Moretti, F. Gea, C. Colletta, R. Perez-Alvarez, X. Forns, J. R. Larrubia, J. Arenas, J. CrespoV. Calvaruso, F. Ceccherini Silberstein, P. Maisonneuve, A. Craxì, J. L. Calleja, V. Di Marco, M. Monti, G. Rizzardini, S. Landonio, M. Rizzetto, L. E. Lapini, V. Piazzolla, A. Picciotto, A. Alberti, L. Cavaletto, M. Koch, M. Massari, L. Muratori, V. Cipriano, A. Montineri, C. Iacobello, S. Fangazio, M. Pirisi, A. Colombo, G. Bellati, F. Mazzotta, P. Pierotti, A. Traverso, G. Serviddio, M. Russello, T. Santantonio, D. Drenaggi, E. Marchionne, M. Zuin, M. Delliponti, F. Farina, P. Andreone, A. Scuteri, M. Galli, E. G. Giannini, A. Nerli, S. Carbonai, N. Coppola, M. Montalbano, V. Portelli, A. Di Biagio, L. A. Nicolini, C. Mastroianni, S. Madonia, A. Licata, G. Montalto, L. Giannitrapani, M. Mondelli, A. Pellicelli, P. Toniutto, G. Borgia, I. Gentile, M. De Luca, G. G. Di Costanzo, G. Corti, M. Sousa, M. B. Delgado, J. De La Revilla, J. M. Navarro, R. Barcena, M. Romero-Gomez, C. M. Fernandez-Rodriguez, I. Narvaez, J. C. Erdozain, E. Molina, I. Fernandez, B. Cuenca, R. Planas, J. Garcia-Samaniego, J. M. Ladero, J. M. Gonzalez, M. A. Serra, I. Castellote, R. Sola, T. Anton, I. Ryan, F. Gonzalez, E. Martinez, J. Portu

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In many countries, first-generation protease inhibitors (PIs)/peginterferon/ribavirin (P/R) still represent the only treatment option for HCV-infected patients. Subjects with advanced disease and previous failure to P/R urgently need therapy, but they are under-represented in clinical trials. All treatment-experienced F3/4 Metavir patients who received boceprevir (BOC)+P/R in the Italian-Spanish Name Patient Program have been included in this study. Multivariate logistic regression analysis (MLR) was used to identify baseline and on-treatment predictors of SVR and adverse events (AEs). Four hundred and sixteen patients, mean age 57.7 (range 25-78 years), 70% males, 69.5% (289/416) F4, 14% (41/289) Child-Pugh class A6, 24% (70/289) with varices and 42% (173/416) prior null responders to P/R, were analysed. Overall, SVR rate (all 381 patients who received one dose of BOC) was 49%, (58% in F3, 45% in F4, 61% in relapsers, 51% in partial, 38% in null responders, and 72% in subjects with undetectable HCV-RNA at treatment-week (TW)8. Among patients with TW8 HCV-RNA ≥ 1000 IU/L, SVR was 8% (negative predictive value = 92%). Death occurred in 3 (0.8%) patients, while decompensation and infections were observed in 2.9% and 11%, respectively. At MLR, SVR predictors were TW4 HCV-RNA ≥ 1log10-decline from baseline, undetectable TW8 HCV-RNA, prior relapse, albumin levels ≥3.5 g/dL and platelet counts ≥100 000/lL. Metavir F4, Child-Pugh A6, albumin, platelets, age and female gender were associated with serious and haematological AEs. Among treatment-experienced patients with advanced liver disease eligible for IFN-based therapy, TW8 HCV-RNA characterised the subset with either high or poor likelihood of achieving SVR. Using TW8 HCV-RNA as a futility rule, BOC/P/R appears to have a favourable benefit-risk profile.

Original languageEnglish
Pages (from-to)469-480
Number of pages12
JournalJournal of Viral Hepatitis
Volume22
Issue number5
DOIs
Publication statusPublished - May 1 2015

Fingerprint

Ribavirin
Names
Liver Diseases
RNA
Therapeutics
Albumins
Logistic Models
Regression Analysis
Medical Futility
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
Varicose Veins
Protease Inhibitors
Platelet Count
Blood Platelets
Clinical Trials
Recurrence
Infection

Keywords

  • boceprevir
  • cirrhosis
  • first-generation protease inhibitors
  • hepatitis C
  • IFN-based therapy

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases
  • Virology
  • Medicine(all)

Cite this

Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease : The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. / Bruno, S.; Bollani, S.; Zignego, A. L.; Pascasio, J. M.; Magni, C.; Ciancio, A.; Caremani, M.; Mangia, A.; Marenco, S.; Piovesan, S.; Chemello, L.; Babudieri, S.; Moretti, A.; Gea, F.; Colletta, C.; Perez-Alvarez, R.; Forns, X.; Larrubia, J. R.; Arenas, J.; Crespo, J.; Calvaruso, V.; Ceccherini Silberstein, F.; Maisonneuve, P.; Craxì, A.; Calleja, J. L.; Di Marco, V.; Monti, M.; Rizzardini, G.; Landonio, S.; Rizzetto, M.; Lapini, L. E.; Piazzolla, V.; Picciotto, A.; Alberti, A.; Cavaletto, L.; Koch, M.; Massari, M.; Muratori, L.; Cipriano, V.; Montineri, A.; Iacobello, C.; Fangazio, S.; Pirisi, M.; Colombo, A.; Bellati, G.; Mazzotta, F.; Pierotti, P.; Traverso, A.; Serviddio, G.; Russello, M.; Santantonio, T.; Drenaggi, D.; Marchionne, E.; Zuin, M.; Delliponti, M.; Farina, F.; Andreone, P.; Scuteri, A.; Galli, M.; Giannini, E. G.; Nerli, A.; Carbonai, S.; Coppola, N.; Montalbano, M.; Portelli, V.; Di Biagio, A.; Nicolini, L. A.; Mastroianni, C.; Madonia, S.; Licata, A.; Montalto, G.; Giannitrapani, L.; Mondelli, M.; Pellicelli, A.; Toniutto, P.; Borgia, G.; Gentile, I.; De Luca, M.; Di Costanzo, G. G.; Corti, G.; Sousa, M.; Delgado, M. B.; De La Revilla, J.; Navarro, J. M.; Barcena, R.; Romero-Gomez, M.; Fernandez-Rodriguez, C. M.; Narvaez, I.; Erdozain, J. C.; Molina, E.; Fernandez, I.; Cuenca, B.; Planas, R.; Garcia-Samaniego, J.; Ladero, J. M.; Gonzalez, J. M.; Serra, M. A.; Castellote, I.; Sola, R.; Anton, T.; Ryan, I.; Gonzalez, F.; Martinez, E.; Portu, J.

In: Journal of Viral Hepatitis, Vol. 22, No. 5, 01.05.2015, p. 469-480.

Research output: Contribution to journalArticle

Bruno, S, Bollani, S, Zignego, AL, Pascasio, JM, Magni, C, Ciancio, A, Caremani, M, Mangia, A, Marenco, S, Piovesan, S, Chemello, L, Babudieri, S, Moretti, A, Gea, F, Colletta, C, Perez-Alvarez, R, Forns, X, Larrubia, JR, Arenas, J, Crespo, J, Calvaruso, V, Ceccherini Silberstein, F, Maisonneuve, P, Craxì, A, Calleja, JL, Di Marco, V, Monti, M, Rizzardini, G, Landonio, S, Rizzetto, M, Lapini, LE, Piazzolla, V, Picciotto, A, Alberti, A, Cavaletto, L, Koch, M, Massari, M, Muratori, L, Cipriano, V, Montineri, A, Iacobello, C, Fangazio, S, Pirisi, M, Colombo, A, Bellati, G, Mazzotta, F, Pierotti, P, Traverso, A, Serviddio, G, Russello, M, Santantonio, T, Drenaggi, D, Marchionne, E, Zuin, M, Delliponti, M, Farina, F, Andreone, P, Scuteri, A, Galli, M, Giannini, EG, Nerli, A, Carbonai, S, Coppola, N, Montalbano, M, Portelli, V, Di Biagio, A, Nicolini, LA, Mastroianni, C, Madonia, S, Licata, A, Montalto, G, Giannitrapani, L, Mondelli, M, Pellicelli, A, Toniutto, P, Borgia, G, Gentile, I, De Luca, M, Di Costanzo, GG, Corti, G, Sousa, M, Delgado, MB, De La Revilla, J, Navarro, JM, Barcena, R, Romero-Gomez, M, Fernandez-Rodriguez, CM, Narvaez, I, Erdozain, JC, Molina, E, Fernandez, I, Cuenca, B, Planas, R, Garcia-Samaniego, J, Ladero, JM, Gonzalez, JM, Serra, MA, Castellote, I, Sola, R, Anton, T, Ryan, I, Gonzalez, F, Martinez, E & Portu, J 2015, 'Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program', Journal of Viral Hepatitis, vol. 22, no. 5, pp. 469-480. https://doi.org/10.1111/jvh.12342
Bruno, S. ; Bollani, S. ; Zignego, A. L. ; Pascasio, J. M. ; Magni, C. ; Ciancio, A. ; Caremani, M. ; Mangia, A. ; Marenco, S. ; Piovesan, S. ; Chemello, L. ; Babudieri, S. ; Moretti, A. ; Gea, F. ; Colletta, C. ; Perez-Alvarez, R. ; Forns, X. ; Larrubia, J. R. ; Arenas, J. ; Crespo, J. ; Calvaruso, V. ; Ceccherini Silberstein, F. ; Maisonneuve, P. ; Craxì, A. ; Calleja, J. L. ; Di Marco, V. ; Monti, M. ; Rizzardini, G. ; Landonio, S. ; Rizzetto, M. ; Lapini, L. E. ; Piazzolla, V. ; Picciotto, A. ; Alberti, A. ; Cavaletto, L. ; Koch, M. ; Massari, M. ; Muratori, L. ; Cipriano, V. ; Montineri, A. ; Iacobello, C. ; Fangazio, S. ; Pirisi, M. ; Colombo, A. ; Bellati, G. ; Mazzotta, F. ; Pierotti, P. ; Traverso, A. ; Serviddio, G. ; Russello, M. ; Santantonio, T. ; Drenaggi, D. ; Marchionne, E. ; Zuin, M. ; Delliponti, M. ; Farina, F. ; Andreone, P. ; Scuteri, A. ; Galli, M. ; Giannini, E. G. ; Nerli, A. ; Carbonai, S. ; Coppola, N. ; Montalbano, M. ; Portelli, V. ; Di Biagio, A. ; Nicolini, L. A. ; Mastroianni, C. ; Madonia, S. ; Licata, A. ; Montalto, G. ; Giannitrapani, L. ; Mondelli, M. ; Pellicelli, A. ; Toniutto, P. ; Borgia, G. ; Gentile, I. ; De Luca, M. ; Di Costanzo, G. G. ; Corti, G. ; Sousa, M. ; Delgado, M. B. ; De La Revilla, J. ; Navarro, J. M. ; Barcena, R. ; Romero-Gomez, M. ; Fernandez-Rodriguez, C. M. ; Narvaez, I. ; Erdozain, J. C. ; Molina, E. ; Fernandez, I. ; Cuenca, B. ; Planas, R. ; Garcia-Samaniego, J. ; Ladero, J. M. ; Gonzalez, J. M. ; Serra, M. A. ; Castellote, I. ; Sola, R. ; Anton, T. ; Ryan, I. ; Gonzalez, F. ; Martinez, E. ; Portu, J. / Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease : The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. In: Journal of Viral Hepatitis. 2015 ; Vol. 22, No. 5. pp. 469-480.
@article{d235d053b01a48aca49267ce1a3a3373,
title = "Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program",
abstract = "In many countries, first-generation protease inhibitors (PIs)/peginterferon/ribavirin (P/R) still represent the only treatment option for HCV-infected patients. Subjects with advanced disease and previous failure to P/R urgently need therapy, but they are under-represented in clinical trials. All treatment-experienced F3/4 Metavir patients who received boceprevir (BOC)+P/R in the Italian-Spanish Name Patient Program have been included in this study. Multivariate logistic regression analysis (MLR) was used to identify baseline and on-treatment predictors of SVR and adverse events (AEs). Four hundred and sixteen patients, mean age 57.7 (range 25-78 years), 70{\%} males, 69.5{\%} (289/416) F4, 14{\%} (41/289) Child-Pugh class A6, 24{\%} (70/289) with varices and 42{\%} (173/416) prior null responders to P/R, were analysed. Overall, SVR rate (all 381 patients who received one dose of BOC) was 49{\%}, (58{\%} in F3, 45{\%} in F4, 61{\%} in relapsers, 51{\%} in partial, 38{\%} in null responders, and 72{\%} in subjects with undetectable HCV-RNA at treatment-week (TW)8. Among patients with TW8 HCV-RNA ≥ 1000 IU/L, SVR was 8{\%} (negative predictive value = 92{\%}). Death occurred in 3 (0.8{\%}) patients, while decompensation and infections were observed in 2.9{\%} and 11{\%}, respectively. At MLR, SVR predictors were TW4 HCV-RNA ≥ 1log10-decline from baseline, undetectable TW8 HCV-RNA, prior relapse, albumin levels ≥3.5 g/dL and platelet counts ≥100 000/lL. Metavir F4, Child-Pugh A6, albumin, platelets, age and female gender were associated with serious and haematological AEs. Among treatment-experienced patients with advanced liver disease eligible for IFN-based therapy, TW8 HCV-RNA characterised the subset with either high or poor likelihood of achieving SVR. Using TW8 HCV-RNA as a futility rule, BOC/P/R appears to have a favourable benefit-risk profile.",
keywords = "boceprevir, cirrhosis, first-generation protease inhibitors, hepatitis C, IFN-based therapy",
author = "S. Bruno and S. Bollani and Zignego, {A. L.} and Pascasio, {J. M.} and C. Magni and A. Ciancio and M. Caremani and A. Mangia and S. Marenco and S. Piovesan and L. Chemello and S. Babudieri and A. Moretti and F. Gea and C. Colletta and R. Perez-Alvarez and X. Forns and Larrubia, {J. R.} and J. Arenas and J. Crespo and V. Calvaruso and {Ceccherini Silberstein}, F. and P. Maisonneuve and A. Crax{\`i} and Calleja, {J. L.} and {Di Marco}, V. and M. Monti and G. Rizzardini and S. Landonio and M. Rizzetto and Lapini, {L. E.} and V. Piazzolla and A. Picciotto and A. Alberti and L. Cavaletto and M. Koch and M. Massari and L. Muratori and V. Cipriano and A. Montineri and C. Iacobello and S. Fangazio and M. Pirisi and A. Colombo and G. Bellati and F. Mazzotta and P. Pierotti and A. Traverso and G. Serviddio and M. Russello and T. Santantonio and D. Drenaggi and E. Marchionne and M. Zuin and M. Delliponti and F. Farina and P. Andreone and A. Scuteri and M. Galli and Giannini, {E. G.} and A. Nerli and S. Carbonai and N. Coppola and M. Montalbano and V. Portelli and {Di Biagio}, A. and Nicolini, {L. A.} and C. Mastroianni and S. Madonia and A. Licata and G. Montalto and L. Giannitrapani and M. Mondelli and A. Pellicelli and P. Toniutto and G. Borgia and I. Gentile and {De Luca}, M. and {Di Costanzo}, {G. G.} and G. Corti and M. Sousa and Delgado, {M. B.} and {De La Revilla}, J. and Navarro, {J. M.} and R. Barcena and M. Romero-Gomez and Fernandez-Rodriguez, {C. M.} and I. Narvaez and Erdozain, {J. C.} and E. Molina and I. Fernandez and B. Cuenca and R. Planas and J. Garcia-Samaniego and Ladero, {J. M.} and Gonzalez, {J. M.} and Serra, {M. A.} and I. Castellote and R. Sola and T. Anton and I. Ryan and F. Gonzalez and E. Martinez and J. Portu",
year = "2015",
month = "5",
day = "1",
doi = "10.1111/jvh.12342",
language = "English",
volume = "22",
pages = "469--480",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "5",

}

TY - JOUR

T1 - Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease

T2 - The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program

AU - Bruno, S.

AU - Bollani, S.

AU - Zignego, A. L.

AU - Pascasio, J. M.

AU - Magni, C.

AU - Ciancio, A.

AU - Caremani, M.

AU - Mangia, A.

AU - Marenco, S.

AU - Piovesan, S.

AU - Chemello, L.

AU - Babudieri, S.

AU - Moretti, A.

AU - Gea, F.

AU - Colletta, C.

AU - Perez-Alvarez, R.

AU - Forns, X.

AU - Larrubia, J. R.

AU - Arenas, J.

AU - Crespo, J.

AU - Calvaruso, V.

AU - Ceccherini Silberstein, F.

AU - Maisonneuve, P.

AU - Craxì, A.

AU - Calleja, J. L.

AU - Di Marco, V.

AU - Monti, M.

AU - Rizzardini, G.

AU - Landonio, S.

AU - Rizzetto, M.

AU - Lapini, L. E.

AU - Piazzolla, V.

AU - Picciotto, A.

AU - Alberti, A.

AU - Cavaletto, L.

AU - Koch, M.

AU - Massari, M.

AU - Muratori, L.

AU - Cipriano, V.

AU - Montineri, A.

AU - Iacobello, C.

AU - Fangazio, S.

AU - Pirisi, M.

AU - Colombo, A.

AU - Bellati, G.

AU - Mazzotta, F.

AU - Pierotti, P.

AU - Traverso, A.

AU - Serviddio, G.

AU - Russello, M.

AU - Santantonio, T.

AU - Drenaggi, D.

AU - Marchionne, E.

AU - Zuin, M.

AU - Delliponti, M.

AU - Farina, F.

AU - Andreone, P.

AU - Scuteri, A.

AU - Galli, M.

AU - Giannini, E. G.

AU - Nerli, A.

AU - Carbonai, S.

AU - Coppola, N.

AU - Montalbano, M.

AU - Portelli, V.

AU - Di Biagio, A.

AU - Nicolini, L. A.

AU - Mastroianni, C.

AU - Madonia, S.

AU - Licata, A.

AU - Montalto, G.

AU - Giannitrapani, L.

AU - Mondelli, M.

AU - Pellicelli, A.

AU - Toniutto, P.

AU - Borgia, G.

AU - Gentile, I.

AU - De Luca, M.

AU - Di Costanzo, G. G.

AU - Corti, G.

AU - Sousa, M.

AU - Delgado, M. B.

AU - De La Revilla, J.

AU - Navarro, J. M.

AU - Barcena, R.

AU - Romero-Gomez, M.

AU - Fernandez-Rodriguez, C. M.

AU - Narvaez, I.

AU - Erdozain, J. C.

AU - Molina, E.

AU - Fernandez, I.

AU - Cuenca, B.

AU - Planas, R.

AU - Garcia-Samaniego, J.

AU - Ladero, J. M.

AU - Gonzalez, J. M.

AU - Serra, M. A.

AU - Castellote, I.

AU - Sola, R.

AU - Anton, T.

AU - Ryan, I.

AU - Gonzalez, F.

AU - Martinez, E.

AU - Portu, J.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - In many countries, first-generation protease inhibitors (PIs)/peginterferon/ribavirin (P/R) still represent the only treatment option for HCV-infected patients. Subjects with advanced disease and previous failure to P/R urgently need therapy, but they are under-represented in clinical trials. All treatment-experienced F3/4 Metavir patients who received boceprevir (BOC)+P/R in the Italian-Spanish Name Patient Program have been included in this study. Multivariate logistic regression analysis (MLR) was used to identify baseline and on-treatment predictors of SVR and adverse events (AEs). Four hundred and sixteen patients, mean age 57.7 (range 25-78 years), 70% males, 69.5% (289/416) F4, 14% (41/289) Child-Pugh class A6, 24% (70/289) with varices and 42% (173/416) prior null responders to P/R, were analysed. Overall, SVR rate (all 381 patients who received one dose of BOC) was 49%, (58% in F3, 45% in F4, 61% in relapsers, 51% in partial, 38% in null responders, and 72% in subjects with undetectable HCV-RNA at treatment-week (TW)8. Among patients with TW8 HCV-RNA ≥ 1000 IU/L, SVR was 8% (negative predictive value = 92%). Death occurred in 3 (0.8%) patients, while decompensation and infections were observed in 2.9% and 11%, respectively. At MLR, SVR predictors were TW4 HCV-RNA ≥ 1log10-decline from baseline, undetectable TW8 HCV-RNA, prior relapse, albumin levels ≥3.5 g/dL and platelet counts ≥100 000/lL. Metavir F4, Child-Pugh A6, albumin, platelets, age and female gender were associated with serious and haematological AEs. Among treatment-experienced patients with advanced liver disease eligible for IFN-based therapy, TW8 HCV-RNA characterised the subset with either high or poor likelihood of achieving SVR. Using TW8 HCV-RNA as a futility rule, BOC/P/R appears to have a favourable benefit-risk profile.

AB - In many countries, first-generation protease inhibitors (PIs)/peginterferon/ribavirin (P/R) still represent the only treatment option for HCV-infected patients. Subjects with advanced disease and previous failure to P/R urgently need therapy, but they are under-represented in clinical trials. All treatment-experienced F3/4 Metavir patients who received boceprevir (BOC)+P/R in the Italian-Spanish Name Patient Program have been included in this study. Multivariate logistic regression analysis (MLR) was used to identify baseline and on-treatment predictors of SVR and adverse events (AEs). Four hundred and sixteen patients, mean age 57.7 (range 25-78 years), 70% males, 69.5% (289/416) F4, 14% (41/289) Child-Pugh class A6, 24% (70/289) with varices and 42% (173/416) prior null responders to P/R, were analysed. Overall, SVR rate (all 381 patients who received one dose of BOC) was 49%, (58% in F3, 45% in F4, 61% in relapsers, 51% in partial, 38% in null responders, and 72% in subjects with undetectable HCV-RNA at treatment-week (TW)8. Among patients with TW8 HCV-RNA ≥ 1000 IU/L, SVR was 8% (negative predictive value = 92%). Death occurred in 3 (0.8%) patients, while decompensation and infections were observed in 2.9% and 11%, respectively. At MLR, SVR predictors were TW4 HCV-RNA ≥ 1log10-decline from baseline, undetectable TW8 HCV-RNA, prior relapse, albumin levels ≥3.5 g/dL and platelet counts ≥100 000/lL. Metavir F4, Child-Pugh A6, albumin, platelets, age and female gender were associated with serious and haematological AEs. Among treatment-experienced patients with advanced liver disease eligible for IFN-based therapy, TW8 HCV-RNA characterised the subset with either high or poor likelihood of achieving SVR. Using TW8 HCV-RNA as a futility rule, BOC/P/R appears to have a favourable benefit-risk profile.

KW - boceprevir

KW - cirrhosis

KW - first-generation protease inhibitors

KW - hepatitis C

KW - IFN-based therapy

UR - http://www.scopus.com/inward/record.url?scp=84926515857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926515857&partnerID=8YFLogxK

U2 - 10.1111/jvh.12342

DO - 10.1111/jvh.12342

M3 - Article

C2 - 25311757

AN - SCOPUS:84926515857

VL - 22

SP - 469

EP - 480

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 5

ER -